

**TUESDAY, JUNE 27, 2006**

---

**TOPIC: “Clinical Trials Gone Global”**

**SPEAKERS:** **Dr. Sheldon Brookman**, Executive Director, Teijin America Inc.  
**Dr. Kim Wagner**, Vice President, Boston Consulting Group  
**Dr. Susan Sobolov**, Senior Director & Neuroscience Team Leader,  
Pfizer Global Research & Development.

The pharma industry is conducting significantly fewer clinical trials of potential new medicines now than it did in 2001, and the number of principal investigators leading those efforts in the United States has declined even more steeply, according to a study done by the Tufts Center for the Study of Drug Development. New clinical trials are increasingly done abroad, including South America, Eastern Europe and Asia, due to lower costs and often greater professional and public interest. The global clinical trials industry is currently worth an estimated \$10 billion. Global revenues from clinical trials have increased by almost 15% in 2005, and the industry has the potential for considerable growth in the future.

At this program, using some case studies and results from recent research, three experts will examine issues that surround global clinical trials and development, such as market opportunities, how to design global trials, how to handle regulatory issues, data management, patient recruitment and other practical issues.

With an undergraduate degree in industrial pharmacy and graduate degrees in both medicinal chemistry and experimental medicine and surgery, Dr. Sheldon Brookman has over 25 years of experience in the pharmaceutical and CRO industries, both in the U.S. and internationally. He has held executive level positions in clinical development, regulatory, research management and pre-marketing functions and currently heads Clinical Research and Regulatory Affairs at Teijin America.

Dr. Kim Wagner is a vice president in Boston Consulting Group's New York office, a member of the firm's health care and information technology practices, and co-leads its biopharma R&D business. Prior to joining BCG, she was a research associate and teaching fellow at Harvard Medical School. Kim holds a PH.D. in biological chemistry and molecular pharmacology from Harvard University, and M.S. in animal science from Texas A&M University.

Dr. Susan Sobolov has been working the pharmaceutical industry for over 12 years. During the past 5 years she has been leading research and development management teams developing compounds from preclinical to later stage development, both in the US and ex-US. Susan completed a post-doctoral fellowship at Harvard University in biological chemistry and molecular pharmacology after receiving her PhD from Yale University in organic chemistry. Prior to joining Pfizer, she was an assistant professor at Wesleyan University.